

# Resource Summary Report

Generated by [NIF](#) on Aug 28, 2026

## CD19 Antibody, anti-human, APC, REAfinity™

RRID:AB\_2726195

Type: Antibody

---

### Proper Citation

Miltenyi Biotec Cat# 130-113-642, RRID:AB\_2726195

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2726195](http://antibodyregistry.org/AB_2726195)

**Proper Citation:** Miltenyi Biotec Cat# 130-113-642, RRID:AB\_2726195

**Target Antigen:** CD19

**Host Organism:** human

**Clonality:** monoclonal

**Comments:** Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-250. (RRID:AB\_2655809).

**Antibody Name:** CD19 Antibody, anti-human, APC, REAfinity™

**Description:** This monoclonal targets CD19

**Target Organism:** human

**Clone ID:** clone REA675

**Antibody ID:** AB\_2726195

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-113-642

**Record Creation Time:** 20250820T035759+0000

**Record Last Update:** 20250820T173951+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD19 Antibody, anti-human, APC, REAfinity™.

No alerts have been found for CD19 Antibody, anti-human, APC, REAfinity™.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Ghasabeh AS, et al. (2026) Allogeneic CD56 + cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a phase I clinical trial. Cancer immunology, immunotherapy : CII, 75(4).

Decker AH, et al. (2025) Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis. iScience, 28(7), 112957.